153 related articles for article (PubMed ID: 23530551)
1. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies.
Kim KJ; Baek IW; Yoon CH; Kim WU; Cho CS
Br J Haematol; 2013 Jun; 161(5):706-714. PubMed ID: 23530551
[TBL] [Abstract][Full Text] [Related]
2. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
3. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study.
Hisada R; Kato M; Sugawara E; Fujieda Y; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
J Thromb Haemost; 2017 Sep; 15(9):1782-1787. PubMed ID: 28662299
[TBL] [Abstract][Full Text] [Related]
4. Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria.
Demetrio Pablo R; Muñoz P; López-Hoyos M; Calvo V; Riancho L; Martínez-Taboada VM
Med Clin (Barc); 2017 May; 148(9):394-400. PubMed ID: 28153433
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia.
Yang YJ; Yun GW; Song IC; Baek SW; Lee KS; Ryu HW; Lee MW; Lee HJ; Yun HJ; Kim S; Jo DY
Korean J Intern Med; 2011 Dec; 26(4):449-54. PubMed ID: 22205846
[TBL] [Abstract][Full Text] [Related]
6. Identifying additional risk factors for arterial and venous thrombosis among pediatric antiphospholipid antibodies carriers.
Sloan E; Wright T; Zuo Y
Lupus; 2021 Apr; 30(5):828-832. PubMed ID: 33736541
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
Neville C; Rauch J; Kassis J; Chang ER; Joseph L; Le Comte M; Fortin PR
Thromb Haemost; 2003 Jul; 90(1):108-15. PubMed ID: 12876633
[TBL] [Abstract][Full Text] [Related]
8. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
[TBL] [Abstract][Full Text] [Related]
9. [Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome].
Moulis G; Delavigne K; Huguet F; Fortenfant F; Beyne-Rauzy O; Adoue D
Rev Med Interne; 2011 Dec; 32(12):724-9. PubMed ID: 21864953
[TBL] [Abstract][Full Text] [Related]
10. Length of exposure to antiphospholipid antibodies, rather than age, is a risk factor for thrombosis: a retrospective single-centre observational study.
Les I; Parraza N; Anaut P; Eguiluz S; Sánchez C; Preciado ME; Loza JÁ; Andía A
Rheumatol Int; 2018 Feb; 38(2):229-238. PubMed ID: 29124399
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for the Development of the Disease in Antiphospholipid Antibodies Carriers: A Long-term Follow-up Study.
Pablo RD; Cacho PM; López-Hoyos M; Calvo-Río V; Riancho-Zarrabeitia L; Martínez-Taboada VM
Clin Rev Allergy Immunol; 2022 Apr; 62(2):354-362. PubMed ID: 34216367
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study.
Ruffatti A; Del Ross T; Ciprian M; Bertero MT; Sciascia S; Scarpato S; Montecucco C; Rossi S; Caramaschi P; Biasi D; Doria A; Rampudda M; Monica N; Fischetti F; Picillo U; Brucato A; Salvan E; Vittorio P; Meroni P; Tincani A;
Ann Rheum Dis; 2011 Jun; 70(6):1083-6. PubMed ID: 21285115
[TBL] [Abstract][Full Text] [Related]
13. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
15. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.
Moroni G; Ventura D; Riva P; Panzeri P; Quaglini S; Banfi G; Simonini P; Bader R; Meroni PL; Ponticelli C
Am J Kidney Dis; 2004 Jan; 43(1):28-36. PubMed ID: 14712424
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events.
Otomo K; Atsumi T; Amengual O; Fujieda Y; Kato M; Oku K; Horita T; Yasuda S; Koike T
Arthritis Rheum; 2012 Feb; 64(2):504-12. PubMed ID: 21953404
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of antiphospholipid antibody in pediatric patients and review of literature].
Xiao HJ; Yang JY; Gao TJ; Huang JP; Yao Y; Zhang Y
Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):571-3. PubMed ID: 15347440
[TBL] [Abstract][Full Text] [Related]
18. Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.
Žigon P; Podovšovnik A; Ambrožič A; Tomšič M; Hočevar A; Gašperšič N; Rotar Ž; Praprotnik S; Šemrl SS; Čučnik S
Clin Rheumatol; 2019 Feb; 38(2):371-378. PubMed ID: 30099654
[TBL] [Abstract][Full Text] [Related]
19. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus--a meta-analysis.
Wahl DG; Guillemin F; de Maistre E; Perret C; Lecompte T; Thibaut G
Lupus; 1997; 6(5):467-73. PubMed ID: 9229367
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of antiphospholipid antibodies in Syrian patients with thrombosis.
Deeb A; Hamdoun S; Dababo K
Iran J Immunol; 2009 Sep; 6(3):154-9. PubMed ID: 19801789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
